Postoperative Analgesia in Laparoscopic Abdominal Surgery After Exparel Via TAP or Local Infiltration

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-08-31

Study Completion Date

2020-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates differences in how administering liposomal bupivacaine via two different methods affects postoperative pain control in laparoscopic abdominal surgery patients. Half the participants will receive liposomal bupivacaine via a transverses abdominis plane block while the other half will receive liposomal bupivacaine via local infiltration.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy

NCT05224089

Bowel Disease

RECRUITING PHASE4

Exparel Use in Bilateral TAP Blocks for Postoperative Pain Control

NCT03878888

Postoperative Pain Surgery Anesthesia, Local

COMPLETED PHASE4

TAP Block Catheters vs Liposomal Bupivacaine for Pain Control After Colorectal Surgery

NCT03080142

Colorectal Surgery TAP Blocks

COMPLETED PHASE4

Local Anesthetics on Postsurgical Analgesia Following Posterior Colporrhaphy

NCT04032327

Postoperative Pain

COMPLETED PHASE2

Exparel vs. Standard Bupivicaine for Abdominoplasty

NCT01853176

Pain, Postoperative

TERMINATED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Liposomal bupivacaine is a newer formulation of a local anesthetic that is commonly used for local infiltration, peripheral nerve blocks, and neuraxial anesthesia. This new formulation allows the effects of bupivacaine to last up to 72 hours as it is slowly released from a liposome. It is FDA approved for local infiltration and has recently been approved for interscalene blocks.

A transversus abdominis plane block is a fascial plane block that is performed routinely for postoperative pain relief for some abdominal incisions. It is performed by placing local anesthetic between the internal oblique and transverses abdominis muscle planes where it will provide analgesia to several dermatomes of the abdomen in hopes of improving postoperative pain relief and reducing postoperative opioid requirement.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain, Postoperative Anesthesia, Local Anesthesia; Functional Anesthesia Opioid Use

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Unblinded randomized trial

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Local infiltration

Liposomal bupivacaine (266mg) will be directly infiltrated by the surgeon into the surgical laparoscopic wound sites.

Group Type EXPERIMENTAL

Exparel 266 MG Per 20 ML Injection

Intervention Type DRUG

Liposomal bupivacaine

Transversus abdominis plane block

Liposomal bupivacaine (266mg) will be used in a ultrasound guided transversus abdominis plane block.

Group Type EXPERIMENTAL

Exparel 266 MG Per 20 ML Injection

Intervention Type DRUG

Liposomal bupivacaine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Exparel 266 MG Per 20 ML Injection

Liposomal bupivacaine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients scheduled for elective laparoscopic colorectal surgery at UWMC requiring inpatient stay

Exclusion Criteria

* Patients on chronic pain mediations equaling or exceeding \> 25 morphine daily equivalents
* Patients allergic to bupivacaine
* Patients with ASA status IV, V, or VI
* Patients unable to consent
* Patients that are pregnant
* Patients that are incarcerated
* Patients receiving procedures in addition to laparoscopic colorectal procedure
* Patients on systemic anticoagulation precluding them from regional blocks

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes